Corient Private Wealth
SRPT icon

Corient Private Wealth’s Sarepta Therapeutics SRPT Stock Holding History

Corient Private Wealth’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$660K Buy
36,712
+26,880
+273% +$508K ﹤0.01% 2048
2026
Q1 		$212K Sell
9,832
-2,785
-22% -$53.9K ﹤0.01% 2528
2025
Q4 		$272K Buy
12,617
+320
+3% +$6.74K ﹤0.01% 2238
2025
Q3 		$237K Sell
12,297
-143
-1% -$2.55K ﹤0.01% 2270
2025
Q2 		$213K Buy
12,440
+5,281
+74% +$225K ﹤0.01% 2206
2025
Q1 		$457K Buy
7,159
+691
+11% +$72.7K ﹤0.01% 1640
2024
Q4 		$786K Buy
+6,468
New +$793K ﹤0.01% 1420
2024
Q3 		– Sell
-7,828
Closed -$1.24M – 2559
2024
Q2 		$1.24M Buy
7,828
+1,347
+21% +$173K ﹤0.01% 1246
2024
Q1 		$839K Buy
6,481
+492
+8% +$60.3K ﹤0.01% 1373
2023
Q4 		$578K Buy
5,989
+1,941
+48% +$186K ﹤0.01% 1538
2023
Q3 		$491K Buy
+4,048
New +$458K ﹤0.01% 1511
2023
Q1 		– Sell
-3,934
Closed -$510K – 2051
2022
Q4 		$510K Buy
+3,934
New +$456K ﹤0.01% 1139

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Corient Private Wealth's SRPT Position: Q2 2026 in Review

Corient Private Wealth increased its Sarepta Therapeutics (SRPT) stake by 273% in Q2 2026, buying an estimated $508K and bringing the position to 36,712 shares worth $660K. The position accounts for ﹤0.01% of the portfolio, ranked #2048.

Corient Private Wealth first reported a position in SRPT in Q4 2022 and has held it in 12 quarters since. The position peaked at $1.24M in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Corient Private Wealth held 36,712 shares of Sarepta Therapeutics worth $660K as of Q2 2026.
  • Corient Private Wealth bought 26,880 Sarepta Therapeutics shares in Q2 2026, an estimated $508K.
  • Sarepta Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2048 holding.
  • Corient Private Wealth first reported a position in Sarepta Therapeutics in Q4 2022 and has held it in 12 quarters since.
  • Corient Private Wealth's Sarepta Therapeutics position peaked at $1.24M in Q2 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.